The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Clinical Implications of Sarcopenic Obesity in Cancer
Abstract
Sarcopenia has been associated with several negative clinical outcomes in cancer. However, the consequences of sarcopenic obesity, a condition of combined sarcopenia and obesity burden, have been less extensively investigated. The aim of this paper was to review the current evidence on the prevalence and clinical implications of sarcopenic obesity in cancer. A total of 14 studies linking sarcopenic obesity to a clinical outcome in cancer were included. There is considerable inconsistency in methods used to evaluate body composition as well as in the criteria used to define sarcopenic obesity, which limits comparison among studies. Therefore, the prevalence of sarcopenic obesity varied substantially: between 1 and 29 % in studies including individuals from all body mass index categories and between 15 and 36 % for those including obese individuals only. Negative clinical outcomes reported to be associated with sarcopenic obesity included higher risk of dose-limiting toxicity, surgical complications, physical disability, and shorter survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, adverse clinical cancer outcomes reported to be relevant to SO, especially with respect to dose-limiting toxicity, surgical complications, physical disability, and shorter survival (59–61).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [60]
Citations
Cites
(2000) · PubMed · Cited by 13,173
The Disease Burden Associated With Overweight and Obesity
Must, A. (1999) · JAMA · doi:10.1001/jama.282.16.1523 · Cited by 4,827
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
Tilg, H., & Moschen, A. R. (2006) · Nature reviews. Immunology · doi:10.1038/nri1937 · Cited by 3,272
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Self-citationMartin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R. A., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2722 · Cited by 2,761
Bruera, E. D., Kuehn, N., Miller, M. J., Selmser, P., & Macmillan, K. (1991) · Journal of Palliative Care · doi:10.1177/082585979100700202 · Cited by 2,686
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Self-citationShen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692
Research works printed but not linked: 1
- Canadian Cancer Society. 2014 edition of Canadian cancer statistics. 2014. http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on .
Cited by
Sorted by citations
Sarcopenia – Molecular mechanisms and open questions
Wiedmer, P., Jung, T., Castro, J. P., Pomatto, L. C. D., Sun, P. Y., Davies, K. J. A., & Grune, T. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101200 · Cited by 524
“chemotherapy tolerance and toxicity (Anandavadivelan et al., 2016; Carneiro et al., 2016; Prado et al., 2008; Yip et al., 2015).”
Baracos, V. E., & Arribas, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx810 · Cited by 362
“[33] reviewed the clinical implications of SO in cancer reporting negative clinical outcomes associated with SO.”
BackgroundDiabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments
Wang, M., Tan, Y., Shi, Y., Wang, X., Liao, Z., & Wei, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00568 · Cited by 231
A requiem for BMI in the clinical setting
González, M. C., Correia, M. I. T. D., & Heymsfield, S. B. (2017) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000395 · Cited by 209
Differentiating Sarcopenia and Cachexia Among Patients With Cancer
Peterson, S. J., & Mozer, M. (2016) · Nutrition in Clinical Practice · doi:10.1177/0884533616680354 · Cited by 200
“Other complications associated with sarcopenic obesity include poor functional status, worse postoperative outcomes, prolonged hospitalization, and shorter survival.(47) Among patients with cancer, prevalence of sarcopenia ranges from 12%–51% when diagnosed with both body composition and functional assessment tools an…”
Background
Metadata
- Authors
- Carneiro, I. P., Mazurak, V. C., & Prado, C. M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Prado, Carla M.
- Venue
- Current Oncology Reports
- Published
- 2016-08-19
- Volume
- 18
- Issue
- 10
- Pages
- 62-62
- ISSN
- 1523-3790 (ISSN-L)
- 1534-6269
- OpenAlex
- W2518082324
- Cited by
- 162
- References
- 77
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 15 · 2023: 19 · 2022: 15 · 2021: 23 · 2020: 22 · 2019: 19 · 2018: 17 · 2017: 9 · 2016: 1
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Oncology Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
- Keywords
- sarcopenic obesity, sarcopenia, obesity, cancer, body composition, prevalence, dose-limiting toxicity, surgical complications, physical disability, survival, clinical outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Body Composition, Dose-Response Relationship, Drug, Humans, Neoplasms, Obesity, Prevalence, Survival Analysis, Treatment Outcome, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
